Navigation Links
Discovery of 'overdrive' protein could broaden drug design options
Date:2/12/2008

CHAPEL HILL New research by scientists at the University of North Carolina at Chapel Hill shows for the first time that an important family of proteins known to function at the cell surface also functions at a site within the cell.

The findings have potential implications for drug development as they involve G protein-coupled receptors (GPCRs). These molecules are the target of forty to fifty percent of modern medicinal drugs, such as antihistamines and drugs for high blood pressure.

The study identified the first protein to activate the G-protein signaling pathway from within a cell. In humans, reactions to everything from taste and smell to stimulants like adrenaline or caffeine requires G-protein signaling.

Until now, the only known way to turn on a G-protein was via a receptor sitting on a cells surface membrane. This receptor acts like a telegraph operator, accepting outside signals and relaying them inside the cell. It converts an external signal, like caffeine, into action in this case, a nerve signal to the brain.

More than half of all drugs, from asthma and heart medicine to antidepressants, target G-protein receptors. Discovering a protein that activates G-proteins from inside a cell could open up an entirely new pathway for drug development, said Henrik Dohlman, Ph.D., senior study author and a professor of biochemistry and biophysics in UNCs School of Medicine.

No drug is 100 percent effective, 100 percent free of side effects and 100 percent safe. The more options we have biochemically, the more selective we can be in designing new drugs. If we can find another way of modulating G-proteins, we could expand the drug targets that are available to pharmacology, Dohlman said.

The study appeared online Feb.7, 2008, in the journal Current Biology and will be published in the Feb. 14, 2008, print edition. Funding was provided by the National Institutes of Health and a UNC Cell and Molecular Biology Program predoctoral fellowship.

Despite 20 years of study, G-protein signaling continues to produce surprises. The advent of the human genome project revealed that some three percent of our DNA is dedicated to these messenger molecules. However, the genomic data also drew biologists away from the research technique the UNC team used to discover the new protein, Dohlman said. People stopped looking for things that could activate G-proteins using functional criteria, he said. Instead, they searched for new receptors and activators based on common genetic patterns.

Mike Lee, a graduate student in the UNC School of Medicines department of pharmacology, identified the new protein, called Arr4, in yeast cells. Lee employed a mutant form of G-protein to search for any messengers inside the yeast cell with an affinity for G-proteins.

We went looking for things that could activate G-proteins but dont resemble known receptors, Lee said.

He identified seven proteins that werent receptors, but did bind to G-proteins, and did further tests on one of the seven proteins, Arr4, to determine its function.

In yeast, Arr4 is involved in cell fusion, a process in which two yeasts fuse together to form one cell, combining their genetic data. A G-protein coupled receptor (GPCR) controls cell fusion, while Arr4 appears to play a supporting role.

Lee said he thinks that Arr4 may allow the cell to go through several additional rounds of signal activation without needing to go back to the receptor.

Our current thinking is its not so much that this is the ignition for signaling, its more like an overdrive. Once the pathway is activated by the hormone outside, Arr4 sustains the activity inside, Lee said. What we dont know is if Arr4 is itself simulated by some signal, and of course were very interested in finding out if thats the case.


'/>"/>

Contact: Leslie Lang
llang@med.unc.edu
919-843-9687
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: